Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP326675.RAVxB43Mpw7iNUDYOHBxpkqyDNqxFFp435cY-K5sFCQ0c130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP326675.RAVxB43Mpw7iNUDYOHBxpkqyDNqxFFp435cY-K5sFCQ0c130_provenance.
• NP326822.RAbV6ojU-G9JDl-5pAsY30n7qoITRQsB9xf9nuzrvRfhw130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP326822.RAbV6ojU-G9JDl-5pAsY30n7qoITRQsB9xf9nuzrvRfhw130_provenance.
• NP329072.RAU6sYMgDYzTuO51qbzt2z_n_Rj5KXaYZnJE8Htr-PXkg130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP329072.RAU6sYMgDYzTuO51qbzt2z_n_Rj5KXaYZnJE8Htr-PXkg130_provenance.
• NP848256.RAfSznwrsWFejvfxPOQq301QkuCZWWQGPq-t_2eRVObi4130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP848256.RAfSznwrsWFejvfxPOQq301QkuCZWWQGPq-t_2eRVObi4130_provenance.
• NP848397.RAYXutER5LVBnM6x-dcLd8fdLIQCs2g-66rClqUeifB60130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP848397.RAYXutER5LVBnM6x-dcLd8fdLIQCs2g-66rClqUeifB60130_provenance.
• NP644575.RAekWs93jWnxhqW9Qne5Xo1nD0MYtwZvtgyV3YY5f8cMY130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP644575.RAekWs93jWnxhqW9Qne5Xo1nD0MYtwZvtgyV3YY5f8cMY130_provenance.
• NP879815.RAajWam7jkMogGa_fuvoW97P4ToE_osvZDKyjZtc7XhYk130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP879815.RAajWam7jkMogGa_fuvoW97P4ToE_osvZDKyjZtc7XhYk130_provenance.
• NP881719.RAWsd7-RL69YbcSYAkrjDfU86-ZHN5KSD4LAnEE4rkDc8130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881719.RAWsd7-RL69YbcSYAkrjDfU86-ZHN5KSD4LAnEE4rkDc8130_provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1124478.RAZs9A23NNPQ5Aq9XmKIxELZuwOmekLtTSM-0D-1zUgpY130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124478.RAZs9A23NNPQ5Aq9XmKIxELZuwOmekLtTSM-0D-1zUgpY130_provenance.
• NP1124482.RAcZTP5AQXZcBBPc3qCys0dZLE7KF7W48laQVtm8t_oV0130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124482.RAcZTP5AQXZcBBPc3qCys0dZLE7KF7W48laQVtm8t_oV0130_provenance.
• NP1124489.RAYilt2o1Crs4ZB0GPWR_KNHtCmM5d0LEOQjrZ5K5qNvY130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124489.RAYilt2o1Crs4ZB0GPWR_KNHtCmM5d0LEOQjrZ5K5qNvY130_provenance.
• NP1124490.RAQ5GWDhJ3zzV0-V31yJPgf0xUJaYvHFo5zJ55f371Rkk130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124490.RAQ5GWDhJ3zzV0-V31yJPgf0xUJaYvHFo5zJ55f371Rkk130_provenance.
• NP1124481.RAAt1Dt31C21r6hhG8HdaDEWFG97moVihFVkNSryK4dJY130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124481.RAAt1Dt31C21r6hhG8HdaDEWFG97moVihFVkNSryK4dJY130_provenance.
• NP786819.RApjkEPVwjbHoUiz6Qoa-_ezbNQLJ83-vr6dMQlzxKxZ0130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP786819.RApjkEPVwjbHoUiz6Qoa-_ezbNQLJ83-vr6dMQlzxKxZ0130_provenance.
• NP822801.RAtw8zyrU1Mjex7w7765kqeFQ3bJtF9MmJ603bejoxgXA130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP822801.RAtw8zyrU1Mjex7w7765kqeFQ3bJtF9MmJ603bejoxgXA130_provenance.
• NP879954.RAtHFaNvtrd-faTcxsrFUCdbudugdREot_ZKiNPxCiP40130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP879954.RAtHFaNvtrd-faTcxsrFUCdbudugdREot_ZKiNPxCiP40130_provenance.
• NP1124479.RAqx9gS9D20OXDORwkQp0SZJ463PJWHaF5tgurHXzpxng130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124479.RAqx9gS9D20OXDORwkQp0SZJ463PJWHaF5tgurHXzpxng130_provenance.
• NP1124486.RAvaYdllF0F5tUu67Hxk-awNGqMObtA3YVveJ3YhouyW4130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124486.RAvaYdllF0F5tUu67Hxk-awNGqMObtA3YVveJ3YhouyW4130_provenance.
• NP1124491.RAiX5YqvbR04HUjGKvF7F6pdP5kv6PCPO1Ej3YXMicojk130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124491.RAiX5YqvbR04HUjGKvF7F6pdP5kv6PCPO1Ej3YXMicojk130_provenance.
• NP1124492.RApm0B3nD4m5OcFWyUORtWhiND8dNxLGdQxSy-P5umU1Y130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124492.RApm0B3nD4m5OcFWyUORtWhiND8dNxLGdQxSy-P5umU1Y130_provenance.
• NP1124493.RAkPJQmc15ml9p0P7kHOQJKD_af9svI7pa70vbXuU7voY130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124493.RAkPJQmc15ml9p0P7kHOQJKD_af9svI7pa70vbXuU7voY130_provenance.
• NP329262.RA-6HVmomfEAlgnTjK89J5WUI9niLHZBEaMwCeYyaioHY130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP329262.RA-6HVmomfEAlgnTjK89J5WUI9niLHZBEaMwCeYyaioHY130_provenance.
• NP644146.RAGDH-Uf1IOXr4q9O_9ezRx01KoFTfQCnBN7p2DaEcqP0130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP644146.RAGDH-Uf1IOXr4q9O_9ezRx01KoFTfQCnBN7p2DaEcqP0130_provenance.
• NP881579.RAKzwa_SDm-vg_72-PIRASQZ2r9fbNd0ZJ2O54PBZz27w130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881579.RAKzwa_SDm-vg_72-PIRASQZ2r9fbNd0ZJ2O54PBZz27w130_provenance.
• NP1124484.RANWZ4epPFG-035C2P9TLkG3dfbl_9DXn7kOpX0gEiNh8130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124484.RANWZ4epPFG-035C2P9TLkG3dfbl_9DXn7kOpX0gEiNh8130_provenance.
• NP786973.RA_LEBTXNvTNAw0RrFxo8VWrvhcl6BiO1GAJX-ZOkXnRg130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP786973.RA_LEBTXNvTNAw0RrFxo8VWrvhcl6BiO1GAJX-ZOkXnRg130_provenance.
• NP822659.RA6FjvTbM_oQ4s3_VFXGaId_L42IfyVo1flqiFhUq0aXw130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP822659.RA6FjvTbM_oQ4s3_VFXGaId_L42IfyVo1flqiFhUq0aXw130_provenance.
• NP1124480.RA2jMvctlvvBxBux3beSpFALAuLAhE01wih5oHLgIgr5Q130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124480.RA2jMvctlvvBxBux3beSpFALAuLAhE01wih5oHLgIgr5Q130_provenance.
• NP1124488.RAzEagV323LMF8GwSVHDsSzR9Qof49Z5y636Aj5HVOMms130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124488.RAzEagV323LMF8GwSVHDsSzR9Qof49Z5y636Aj5HVOMms130_provenance.
• NP1124494.RA7WWJx_c-FO4reMczjOlfHnSz4z9qN4S4qssDhkcFDrY130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124494.RA7WWJx_c-FO4reMczjOlfHnSz4z9qN4S4qssDhkcFDrY130_provenance.
• NP1124495.RA5sjZdWVVic_zc9X3SlgP9GnZclGa_a55XBIBLICGJIg130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124495.RA5sjZdWVVic_zc9X3SlgP9GnZclGa_a55XBIBLICGJIg130_provenance.
• NP1124496.RA_ySHQFRMb9ulcZ-w4aysSyut9SWKF6p9S5_K4SAcinQ130_assertion description "[14-3-3? attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124496.RA_ySHQFRMb9ulcZ-w4aysSyut9SWKF6p9S5_K4SAcinQ130_provenance.